Healthcare / Diagnostics & ResearchTokyo
$3450.00
+75.00 (+2.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-849.0M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$129.3B
P/E
17.0x
↓EV/EBITDA
4.1x
↓ROE
4.8%
↑Gross Margin
32.0%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.4%
FCF CAGR
—
FCF margin
-0.6%
FCF / Net income
-0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $143.19B · net income $6.26B · FCF $-849.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $143.19B | $143.19B | $137.96B | $159.46B | $186.07B |
| Net Income | $6.26B | $6.26B | $6.03B | $15.58B | $33.74B |
| EBITDA | $17.51B | $17.51B | $16.33B | $30.48B | $56.16B |
| EPS | 160.55 | 160.55 | 154.74 | 395.62 | 832.62 |
| Gross Margin | 32.0% | 32.0% | 33.1% | 38.5% | 46.7% |
| Operating Margin | 6.5% | 6.5% | 6.6% | 15.0% | 26.3% |
| Net Margin | 4.4% | 4.4% | 4.4% | 9.8% | 18.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 |
| Current Ratio | 2.49 | 2.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-849.0M | $-849.0M | $-6.48B | $5.28B | $38.52B |
| Returns | |||||
| ROE | 4.8% | 4.8% | 4.8% | 12.7% | 29.0% |
| Valuation | |||||
| P/E | 16.97 | 16.97 | 18.90 | 7.63 | 3.87 |
| EV/EBITDA | 4.13 | 4.13 | 2.77 | 1.20 | 0.75 |
| P/B | 1.04 | 1.04 | 0.91 | 0.97 | 1.12 |
| Growth & Yield | |||||
| Revenue Growth | 3.8% | 3.8% | -13.5% | -14.3% | — |
| EPS Growth | 3.8% | 3.8% | -60.9% | -52.5% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.0%
EPS terminal req.
$306.13
Spread vs growth
-20.2%
5Y implied EPS CAGR
18.2%
EPS terminal req.
$370.42
Spread vs growth
-14.4%
10Y implied EPS CAGR
14.0%
EPS terminal req.
$596.56
Spread vs growth
-10.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.7%
Start / end P/E
18.7x → 22.2x
EPS bridge
154.74 → 160.55
Residual
+0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.